RTW Investments, LP and Roderick Wong, M.D. filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 8,491,525 shares of Replimune Group, Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: RTW Investments, LP and Roderick Wong each report beneficial ownership of 8,491,525 shares of Replimune Group, Inc. common stock.
- Percent of class: The 8,491,525 shares represent 9.0% of the class, calculated based on 94,219,634 shares outstanding as of August 11, 2026.
- Shared voting and dispositive power: Both reporting persons report 0 shares with sole voting or sole dispositive power; all 8,491,525 shares are held with shared voting and shared dispositive power.
- Triggering event date: The filing was triggered by an event dated September 30, 2026.
- Shares held through RTW Funds: According to the filing, the shares are directly held by funds managed by RTW Investments (the "RTW Funds"), which have the right to receive dividends from, or proceeds from the sale of, the shares reported.
- Filer identity: RTW Investments, LP is a Delaware limited partnership and investment adviser; Roderick Wong, M.D. is its Managing Partner and Chief Investment Officer and a U.S. citizen.
RTW Investments and Roderick Wong Disclose 9.0% Position in Replimune Group
RTW Investments, LP and Roderick Wong, M.D. jointly filed Amendment No. 2 to Schedule 13G with the SEC on November 16, 2026, covering shares of Replimune Group, Inc. (NASDAQ:REPL) common stock, par value $0.001 per share (CUSIP: 76029N106). The filing was triggered by an event dated September 30, 2026, and reports beneficial ownership as of that date. The shares outstanding figure used to calculate the percentage - 94,219,634 - was drawn from the company's Quarterly Report on Form 10-Q filed with the SEC on August 14, 2026, according to the filing.
The filing identifies two reporting persons. RTW Investments, LP is described as a Delaware limited partnership and investment adviser to the RTW Funds, which directly hold the shares. Roderick Wong, M.D. is identified as the Managing Partner and Chief Investment Officer of RTW Investments. Both reporting persons disclose the same aggregate beneficial ownership of 8,491,525 shares, representing 9.0% of the class, with all shares held under shared voting power and shared dispositive power and none under sole voting or sole dispositive power.
The filing states that "the RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein." The filing also includes a certification that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The business address for both reporting persons is listed as 40 10th Avenue, Floor 7, New York, New York 10014.
What Was Disclosed
RTW Investments, LP and Roderick Wong, M.D. filed Amendment No. 2 to Schedule 13G disclosing shared beneficial ownership of 8,491,525 shares of Replimune Group, Inc. common stock, equal to 9.0% of the class, as of September 30, 2026.




Please wait processing your request...